An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C (NPC-1)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

30 Jul 2021 According to a Cyclo Therapeutics media release, data are being presented at the International Niemann Pick Disease Foundation biennial meeting.
30 Jul 2021 Results presented in a Cyclo Therapeutics Media Release.
30 Jul 2021 According to a Cyclo Therapeutics media release, data are being presented at the 2021 National Niemann Pick Disease Foundation Family Support & Medical Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com